ENDP · Endo International PLC - Financials

Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.

Annual Quarterly

Income Statement

Line item	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018
Revenue	$2.01B	$2.32B	$2.99B	$2.90B	$2.91B	$2.95B
Cost of Revenue	$946.41M	$1.09B	$1.22B	$1.44B	$1.57B	$1.63B
Gross Profit	$1.07B	$1.23B	$1.77B	$1.46B	$1.35B	$1.32B
R&D	$115.46M	$125.57M	$148.56M	$158.90M	$130.73M	$185.83M
SG&A	$567.73M	$777.17M	$861.76M	$698.51M	$632.42M	$646.04M
Total Operating Expenses	-	-	-	-	-	-
D&A	$306.45M	$391.63M	$457.10M	$518.81M	$69.00M	$101.37M
Operating Income	($2.39B)	($2.89B)	($546.60M)	($26.52M)	($344.90M)	($469.13M)
Interest Expense	$0	$349.78M	$562.35M	$532.94M	-	-
Income Tax	$55.86M	$21.52M	$22.48M	($273.98M)	$15.68M	$22.93M
Net Income	($2.45B)	($2.92B)	($613.25M)	$183.94M	($422.64M)	($1.03B)
EPS - Basic	($10.42)	($12.45)	($2.63)	$0.80	($1.87)	($4.61)
EPS - Diluted	($10.42)	($12.45)	($2.63)	$0.79	($1.87)	($4.61)

Balance Sheet

Line item	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018
Cash & Equivalents	$777.92M	$1.02B	$1.51B	$1.21B	$1.45B	$1.15B
Accounts Receivable	$386.92M	$493.99M	$592.02M	$511.26M	$467.95M	$470.57M
Inventory	$246.02M	$274.50M	$283.55M	$352.26M	$327.87M	$322.18M
Accounts Payable	$94.73M	$109.03M	$123.13M	$94.41M	$101.53M	$96.02M
Current Assets	$1.67B	$2.08B	$2.71B	$2.41B	$2.59B	$2.34B
Total Assets	$5.14B	$5.76B	$8.77B	$9.26B	$9.39B	$10.13B
Current Liabilities	$538.79M	$689.63M	$1.63B	$1.25B	$1.46B	$1.95B
Long-term Debt	$8.15B	$0	$8.05B	$8.28B	$8.36B	$8.22B
Total Liabilities	-	-	-	-	-	-
Stockholders' Equity	($6.60B)	($4.16B)	($1.24B)	($647.94M)	($866.54M)	($498.28M)
Retained Earnings	($15.35B)	($12.90B)	($9.98B)	($9.37B)	($9.55B)	($9.12B)

Cash Flow

Line item	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018
Operating Cash Flow	$435.10M	$269.19M	$411.05M	$397.39M	$98.05M	$267.27M
Investing Cash Flow	($49.79M)	($133.15M)	($59.54M)	($624.87M)	($60.20M)	($17.90M)
Financing Cash Flow	($604.63M)	($513.87M)	($105.48M)	($108.57M)	$204.60M	($81.57M)
CapEx	$94.33M	$99.72M	$77.93M	$69.97M	$63.85M	$83.40M
Free Cash Flow	$340.77M	$169.47M	$333.12M	$327.42M	$34.20M	$183.87M

Ratios

Metric	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018
Profitability
Gross margin	53.0%	52.9%	59.2%	50.3%	46.2%	44.6%
Operating margin	-118.9%	-124.5%	-18.3%	-0.9%	-11.8%	-15.9%
EBITDA margin	-103.7%	-107.7%	-3.0%	17.0%	-9.5%	-12.5%
Net margin	-121.8%	-126.1%	-20.5%	6.3%	-14.5%	-35.0%
Free cash flow margin	16.9%	7.3%	11.1%	11.3%	1.2%	6.2%
FCF / Net income	-0.14	-0.06	-0.54	1.78	-0.08	-0.18
R&D / Revenue	5.7%	5.4%	5.0%	5.5%	4.5%	6.3%
SG&A / Revenue	28.2%	33.5%	28.8%	24.1%	21.7%	21.9%
Effective tax rate	-	-	-	-	-	-
Return on assets	-47.7%	-50.8%	-7.0%	2.0%	-4.5%	-10.2%
Return on equity	37.1%	70.2%	49.3%	-28.4%	48.8%	207.0%
Return on invested capital	-121.9%	-	-6.3%	-0.3%	-3.6%	-4.8%
Liquidity
Current ratio	3.10	3.01	1.67	1.92	1.77	1.20
Quick ratio	2.64	2.61	1.49	1.64	1.55	1.04
Cash ratio	1.44	1.48	0.92	0.97	1.00	0.59
Leverage
Debt / Equity	-1.23	0.00	-6.47	-12.78	-9.65	-16.51
Debt / Assets	1.59	0.00	0.92	0.89	0.89	0.81
Debt / EBITDA	-	-	-	16.82	-	-
Interest coverage	-	-8.3x	-1.0x	-0.0x	-	-
Equity multiplier	-0.78	-1.38	-7.05	-14.30	-10.84	-20.33
Liabilities / Assets	-	-	-	-	-	-
Efficiency
Asset turnover	0.39	0.40	0.34	0.31	0.31	0.29
Inventory turnover	3.85	3.98	4.31	4.10	4.79	5.06
Days sales outstanding	70d	78d	72d	64d	59d	58d
Days inventory outstanding	95d	92d	85d	89d	76d	72d
Days payable outstanding	37d	36d	37d	24d	24d	21d
Cash conversion cycle	129d	133d	120d	130d	111d	109d
Valuation
P / E	-	-	-	-	-	-
P / B	-	-	-	-	-	-
P / S	-	-	-	-	-	-
EV / EBITDA	-	-	-	-	-	-
Growth
Revenue growth (YoY)	-13.3%	-22.5%	3.1%	-0.4%	-1.1%	-15.0%
Revenue CAGR (3y)	-11.5%	-7.3%	0.5%	-5.8%	-10.1%	-3.4%
Revenue CAGR (5y)	-7.4%	-7.7%	-5.7%	-2.3%	0.7%	-
Gross profit growth (YoY)	-13.2%	-30.8%	21.3%	8.6%	2.3%	6.1%
Operating income growth (YoY)	17.2%	-428.4%	-1961.3%	92.3%	26.5%	51.1%
Net income growth (YoY)	16.2%	-376.7%	-	-	59.0%	49.3%
EPS growth (YoY)	16.3%	-373.4%	-	-	59.4%	49.5%
EPS CAGR (3y)	-	-	-	-	-	-
EPS CAGR (5y)	-	-	-	-	-	-
FCF growth (YoY)	101.1%	-49.1%	1.7%	857.4%	-81.4%	-57.1%
FCF CAGR (5y)	13.1%	-16.9%	-2.9%	-	-44.2%	-
Book value growth (YoY)	-58.5%	-234.6%	-92.0%	25.2%	-73.9%	-

Sales by segment

From XBRL dimensional facts in the 10-K period ending 2023-12-31.

Business segments

$2.01B total

Branded Pharmaceuticals Segment$859.09M · 42.7%

Generic Pharmaceuticals Segment$650.35M · 32.3%

Sterile Injectables Segment$429.56M · 21.4%

International Pharmaceuticals Segment$72.52M · 3.6%

Product / service

$2.15B total

Specialty Products$645.66M · 30.1%

Xiaflex$475.01M · 22.1%

Other Sterile Injectables$236.47M · 11.0%

Established Products$213.43M · 9.9%

PERCOCET$106.38M · 5.0%

Adrenalin$99.91M · 4.7%

SUPPRELINLA$96.85M · 4.5%

Vasostrict$93.18M · 4.3%

Other Specialty Products$73.80M · 3.4%

Other Established Products$64.59M · 3.0%

Lidoderm$42.46M · 2.0%

Stability scores

Piotroski F-score

FY 2023 · 9-point quality

6/9

Neutral

✗Net income positive
✓Operating cash flow positive
✓ROA improved YoY
✓Cash flow > net income
✗Long-term debt decreased
✓Current ratio improved
✓No share dilution
✓Gross margin improved
✗Asset turnover improved

Peer comparison

Same SIC group: Pharmaceutical Preparations

Company	Revenue (last FY)	Net margin	ROE
LLY	$65.18B	31.7%	77.8%
UTHR	$3.18B	41.9%	18.8%
PFE	$62.58B	12.4%	9.0%
ZTS	$9.47B	28.2%	80.2%
VRTX	$12.00B	32.9%	21.2%

Comparing Endo International plc against the 5 most active filers in the same SIC group.